- Home
- MKTW vs QNCX Comparison
MKTW vs QNCX Comparison
Compare MKTW & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTW
- QNCX
- Stock Information
- Founded
- MKTW 1999
- QNCX 2012
- Country
- MKTW United States
- QNCX United States
- Employees
- MKTW N/A
- QNCX N/A
- Industry
- MKTW Computer Software: Prepackaged Software
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MKTW Technology
- QNCX Health Care
- Exchange
- MKTW Nasdaq
- QNCX Nasdaq
- Market Cap
- MKTW 48.2M
- QNCX 47.7M
- IPO Year
- MKTW N/A
- QNCX 2019
- Fundamental
- Price
- MKTW $20.83
- QNCX $1.74
- Analyst Decision
- MKTW
- QNCX Strong Buy
- Analyst Count
- MKTW 0
- QNCX 5
- Target Price
- MKTW N/A
- QNCX $8.00
- AVG Volume (30 Days)
- MKTW 15.8K
- QNCX 231.6K
- Earning Date
- MKTW 08-13-2025
- QNCX 08-12-2025
- Dividend Yield
- MKTW 3.79%
- QNCX N/A
- EPS Growth
- MKTW 207.28
- QNCX N/A
- EPS
- MKTW 3.12
- QNCX N/A
- Revenue
- MKTW $383,217,000.00
- QNCX N/A
- Revenue This Year
- MKTW N/A
- QNCX N/A
- Revenue Next Year
- MKTW N/A
- QNCX N/A
- P/E Ratio
- MKTW $6.75
- QNCX N/A
- Revenue Growth
- MKTW N/A
- QNCX N/A
- 52 Week Low
- MKTW $9.08
- QNCX $0.51
- 52 Week High
- MKTW $23.40
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- MKTW 69.67
- QNCX 55.97
- Support Level
- MKTW $20.12
- QNCX $1.75
- Resistance Level
- MKTW $19.87
- QNCX $2.05
- Average True Range (ATR)
- MKTW 0.79
- QNCX 0.15
- MACD
- MKTW 0.24
- QNCX -0.02
- Stochastic Oscillator
- MKTW 92.10
- QNCX 29.27
About MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.